Gender-related differences in outcome for melanoma patients.

Scoggins, Charles R; Ross, Merrick I; Reintgen, Douglas S; Noyes, R Dirk; Goydos, James S; Beitsch, Peter D; Urist, Marshall M; Ariyan, Stephan; Sussman, Jeffrey J; Edwards, Michael J; Chagpar, Anees B; Martin, Robert C G; Stromberg, Arnold J; Hagendoorn, Lee; McMasters, Kelly M; Sunbelt Melanoma Trial,

People

Help

CiteReady is an online personal knowledge management tool. Click to find out more!

James's Profile

James's Publications

Publicly Shared Collections

Shared by James Goydos

My Publications

Updated in 8/12/2020 12:04:38 PM

Viewed: 146 times

(Journal Article)

Annals of surgery 243 (5): 693-8; discussion 698-700 (2006)

Gender-related differences in outcome for melanoma patients.

Charles R Scoggins , Merrick I Ross , Douglas S Reintgen , R Dirk Noyes , James S Goydos , Peter D Beitsch , Marshall M Urist , Stephan Ariyan , Jeffrey J Sussman , Michael J Edwards , Anees B Chagpar , Robert C G Martin , Arnold J Stromberg , Lee Hagendoorn , Kelly M McMasters , Sunbelt Melanoma Trial

ABSTRACT
To better understand the factors associated with the well-established gender difference in survival for patients with melanoma.Gender is an important factor in patients with cutaneous melanoma. Male patients have a worse outcome when compared with females. The reasons for this difference are poorly understood.This prospective multi-institutional study included patients aged 18 to 70 years with melanomas > or =1.0 mm Breslow thickness. Wide excision and sentinel lymph node (SLN) biopsy was performed in all patients. Clinicopathologic factors, including gender, were assessed and correlated with disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS).A total of 3324 patients were included in the covariate analyses; 1829 patients had follow-up data available and were included in the survival analyses. Median follow-up was 30 months. On univariate analysis, men (n = 1906) were more likely than women to be older than 60 years (P < 0.0001), have thicker melanomas (P < 0.0001), have primary tumor regression (P = 0.0054), ulceration (P < 0.0001), and axial primary tumor location (P < 0.0001). On multivariate analysis, age (P = 0.0002), thickness (P < 0.0001), ulceration (P = 0.015), and location (P < 0.0001) remained significant in the model. There was no difference in the rate of SLN metastasis between men and women (P = 0.37) on multivariate analysis. When factors affecting survival were considered, the prognosis was worse for men as validated by lower DFS (P = 0.0005), DDFS (P < 0.0001), and OS (P < 0.0001).Male gender is associated with a greater incidence of unfavorable primary tumor characteristics without an increased risk for nodal metastasis. Nonetheless, gender is an independent factor affecting survival.

DOI: 10.1097/01.sla.0000216771.81362.6b

ISSN: 0003-4932

Report this

Community
People

Position:	Professor
About me:	James Goydos, MD is widely recognized as an expert in melanoma research & surgical oncology. In his over 20 years of experience as a surgeon, he has conducted research that has translated into patient care, clinical trials, & cutting-edge treatment. His research and clinical trials have recorded growth arrest in melanoma cells, transforming the area of cancer genomics. Goydos has decades of experience as a Professor of Surgery and researcher at UMDNJ Robert Wood Johnson Medical School. He is an advocate for patient privacy and is recognized for leadership in patient care by the Cancer Institute of New Jersey and MRF. By 2020, his work in melanoma & innovative trials have led him to record numerous awards by Castle Connolly. He has helped individuals to better understand the mechanics of melanoma, the invasion of the dermis, and to see that it is not always a death sentence.
ORCID: